Chaubet Lab

Research focus

ERC Consolidator Grant · 2025

Multicomponent Synthetic Conjugation: Redefining Chemical Bioconjugation for the Accelerated Production of Next-Generation Antibody-Drug Conjugates in Oncology

Cancer remains one of the leading causes of death worldwide and in Europe in particular. In the continuous fight against this disease, the recent emergence of antibody-drug conjugates (ADCs) has unveiled tremendous hope for the patients. Composed of an antibody that binds cancer cells selectively, ADCs are capable of delivering a cytotoxic drug into tumors selectively, resulting in targeted cell death. Even though a dozen ADCs has already been marketed, they are still extremely expensive and time-consuming to produce. Besides, their development still lacks guiding principles to maximize their efficacy and increase their safety. At the moment, ADCs share the same structural canvas and are…

From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.